Login to Your Account



TransTech Acquires Entire GKA Program In Diabetes From Novo

By Jim Shrine


Thursday, February 22, 2007
TransTech Pharma Inc. reacquired all rights to a glucokinase activator program that it had partnered with Novo Nordisk A/S more than five years ago, increasing an already healthy pipeline in the area of diabetes. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription